About Sexton Biotechnologies
Sexton Biotechnologies is a company based in Indianapolis (United States) founded in 2019 by Monica Wight and Vicky Tran was acquired by BioLife Solutions in August 2021. Sexton Biotechnologies has raised $5 million across 1 funding round from investors including BioLife Solutions. Sexton Biotechnologies offers products and services including CryoStor, HypoThermosol, and Stemulate hPL. Sexton Biotechnologies operates in a competitive market with competitors including Quanterix, Biocare Medical, Merck, BioLife Solutions and Telesis Bio, among others.
- Headquarter Indianapolis, United States
- Founders Monica Wight, Vicky Tran
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biolife Solutions Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5 M (USD)
in 1 rounds
-
Latest Funding Round
$5 M (USD), Series A
Oct 23, 2019
- Investors
-
Employee Count
Not available
-
Acquired by
BioLife Solutions
(Aug 09, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sexton Biotechnologies
Sexton Biotechnologies offers a comprehensive portfolio of products and services, including CryoStor, HypoThermosol, and Stemulate hPL.
Media for cryopreservation of biologics at low temperatures.
Solution for hypothermic storage and shipping of cells.
Platelet lysate for improving cell growth in research.
Funding Insights of Sexton Biotechnologies
Sexton Biotechnologies has successfully raised a total of $5M through 1 strategic funding round. The most recent funding activity was a Series A round of $5 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sexton Biotechnologies
Sexton Biotechnologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include BioLife Solutions.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
Locked | Locked | Locked |
Investor details for Sexton Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sexton Biotechnologies
Investment portfolio details for Sexton Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sexton Biotechnologies
Detailed financials for Sexton Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sexton Biotechnologies Comparisons
Peer comparison for Sexton Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sexton Biotechnologies
Sexton Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Quanterix, Biocare Medical, Merck, BioLife Solutions and Telesis Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Assay kits for ultra-sensitive biomarker detection are developed.
|
|
| Locked | Locked | Locked |
Primary antibodies and instruments for immunohistochemistry are manufactured.
|
|
| Locked | Locked | Locked |
Merck is engaged in science and technology solutions globally.
|
|
| Locked | Locked | Locked |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| Locked | Locked | Locked |
Online platform offering life sciences reagents and kits
|
|
| Locked | Locked | Locked |
Portfolio of products and services for life science research and clinical diagnostic markets
|
Detailed competitors of Sexton Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sexton Biotechnologies
Complete news archive for Sexton Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sexton Biotechnologies
Sexton Biotechnologies was founded in 2019.
Sexton Biotechnologies is headquartered in Indianapolis, United States. It is registered at Indianapolis, Indiana, United States.
Sexton Biotechnologies is a funded company, having raised a total of $5M across 1 funding round to date.
Sexton Biotechnologies was founded in 2019 in Indianapolis, United States, with a focus on biotechnology for pharmaceutical applications. A portfolio of solutions is provided, including T-Liven PR for enhancing T-cell functions in vitro and in vivo, human platelet lysate, an automated filling system known as AF-500, and cryogenic CellSeal vials. Operations center on process and handling tools for pharma companies and labs.
Sexton Biotechnologies's top competitors include Biocare Medical, Merck and Siemens Healthineers.
Sexton Biotechnologies offers CryoStor, HypoThermosol, and Stemulate hPL.
Sexton Biotechnologies has 1 investor. Key investors include BioLife Solutions.